Titan Biotech has announced its maiden 1:4 bonus issue, with one share to be issued for every four held, subject to shareholder approval. The multibagger stock has gained over 200% in a year and 100% in 2026. Here’s what investors need to know about the bonus issue and eligibility.
This story was originally reported by Economic Times — Markets. As an automated real-time news aggregator, NewsToolBar provides multi-perspective indexing and AI summarization while directing full readership directly to primary publisher sources.
Crowd-sourced evaluation based on verified reader feedback
No reader evaluations recorded yet — be the first to rate the coverage tone above!
Quick Story Reactions:
Sign in or create a free reader account to post comments, upvote analysis, and share your perspective.